{
    "clinical_study": {
        "@rank": "3011", 
        "arm_group": [
            {
                "arm_group_label": "Hizikia Fusiformis extract", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators performed a double-blind parallel study in a group of Subjects Showing\n      Erosive Gastritis who were given Hizikia Fusiformis Extract over a period of 4 weeks.\n      Endoscopic observations were performed before and 4 weeks after the treatment, and the cure\n      and improvement rates were investigated."
        }, 
        "brief_title": "Efficacy and Safety of Hizikia Fusiformis Extract in Subjects Showing Erosive Gastritis", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": "Erosive Gastritis", 
        "condition_browse": {
            "mesh_term": [
                "Gastritis", 
                "Gastrointestinal Hemorrhage", 
                "Acute Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females 19-70 years old\n\n          -  Subjects Showing Erosive Gastritis (endoscopy)\n\n          -  Able to give informed consent\n\n        Exclusion Criteria:\n\n          -  Diagnosed of gastrointestinal disease such as ulcer, cancer within 1 months\n\n          -  Allergic or hypersensitive to any of the ingredients in the test products\n\n          -  History of disease that could interfere with the test products or impede their\n             absorption, such as gastrointestinal disease or gastrointestinal surgery\n\n          -  Taken antibiotics and stomach medicines such as steroid, bismuth compound and proton\n             pump inhibitor within 1 months\n\n          -  Participation in any other clinical trials within past 2 months\n\n          -  Laboratory test, medical or psychological conditions deemed by the investigators to\n             interfere with successful participation in the study\n\n          -  Pregnant or lactating women etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689701", 
            "org_study_id": "PKU-EG-ECKL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hizikia Fusiformis extract", 
                "description": "Hizikia Fusiformis extract(1.3g/d)", 
                "intervention_name": "Hizikia Fusiformis extract", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo(1.3g/d)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Erosive Gastritis", 
            "Hizikia Fusiformis"
        ], 
        "lastchanged_date": "September 20, 2012", 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Chonbuk National University Hospital", 
            "last_name": "Sang-Wook Kim, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Number of erosions was measured in study visit 1(0 week) and visit 3(4 week).", 
                "measure": "Changes in number of erosions", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Score of erosions was measured in study visit 1(0 week) and visit 3(4 week).", 
                "measure": "Changes in score of erosions", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689701"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chonbuk National University Hospital", 
            "investigator_full_name": "Soo-Wan Chae", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "subjects' symptoms was measured in study visit 1(0 week) and visit 3(4 week).", 
                "measure": "Changes in subjects' symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Gastrin was measured in study visit 1(0 week) and visit 3(4 week).", 
                "measure": "Changes in gastrin", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Pepsinogen\u2160 was measured in study visit 1(0 week) and visit 3(4 week).", 
                "measure": "Changes in pepsinogen\u2160", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Pepsinogen\u2161 was measured in study visit 1(0 week) and visit 3(4 week).", 
                "measure": "Changes in pepsinogen\u2161", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Pepsinogen \u2160/\u2161 ratio was measured in study visit 1(0 week) and visit 3(4 week).", 
                "measure": "Changes in pepsinogen \u2160/\u2161 ratio", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Hs-CRP(High Sensitivity C-reactive Protein) was measured in study visit 1(0 week) and visit 3(4 week).", 
                "measure": "Changes in Hs-CRP(High Sensitivity C-reactive Protein)", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Chonbuk National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chonbuk National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}